Generic Name: ripretinib
Drug Class: Targeted Therapy Medications
Approval Status: Approved
Generic Version Available: No
Qinlock is a kinase inhibitor approved for people with previously treated advanced gastrointestinal stromal tumor (GIST).
Qinlock is a tyrosine kinase inhibitor that targets KIT and PDGFRA mutations that drive cancer cell growth. It was approved for people who have already used at least three other kinase inhibitors, including Gleevec (imatinib).
The Phase III INVICTUS trial showed that people treated with Qinlock had a higher response rate and longer progression-free survival than with those who received a placebo. Qinlock was first approved in May 2020.
Qinlock is a tablet taken once daily with or without food.
Common adverse reactions include hair loss, fatigue, nausea, vomiting, abdominal pain, constipation, diarrhea, decreased appetite, muscle pain and hand-foot syndrome (palmar-plantar erythrodysesthesia), with redness, swelling and pain on the palms of the hands and soles of the feet. Potential serious adverse events may include new skin malignancies, severe hypertension, heart problems and slow wound healing. Qinlock can cause fetal harm if used during pregnancy.
Patient Assistance Program Info: https://decipheraaccesspoint.com/
Last Reviewed: May 21, 2020